Shire Investors Say AbbVie Can't Ax Suit Over Failed Inversion
A putative class of Shire PLC shareholders said Monday that AbbVie Inc. must face claims that it harmed investors by downplaying the tax incentives for the drugmakers' $55 billion merger, which...To view the full article, register now.
Already a subscriber? Click here to view full article